Inventor
LAUS REINER
US21 patents
⚠️ This page may combine multiple inventors who share the name “LAUS REINER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
DENDREON CORP
14 patentsUS6080409AJun 27, 2000
Immunostimulatory method
DENDREON CORP152 citations97
US6416958B2Jul 9, 2002
Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody
DENDREON CORP79 citations96
US6210662B1Apr 3, 2001
Immunostimulatory composition
DENDREON CORP47 citations94
US5976546ANov 2, 1999
Immunostimulatory compositions
DENDREON CORP58 citations94
US6194152B1Feb 27, 2001
Prostate tumor polynucleotide compositions and methods of detection thereof
DENDREON CORP53 citations92
US7414108B2Aug 19, 2008
Composition and method for producing an immune response against tumor-related antigens
DENDREON CORP29 citations91
US7597894B2Oct 6, 2009
Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
DENDREON CORP10 citations79
US7060279B2Jun 13, 2006
Compositions and methods for dendritic cell-based immunotherapy
DENDREON CORP10 citations71
US5998599ADec 7, 1999
Growth arrest gene compositions and methods
DENDREON CORP4 citations62
US8362264B2Jan 29, 2013
Compositions and methods for the treatment of disease associated with Trp-p8 expression
DENDREON CORP2 citations60
US7659117B2Feb 9, 2010
Compositions and methods for dendritic cell-based immunotherapy
DENDREON CORP1 citations49
US7560104B2Jul 14, 2009
Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
DENDREON CORP0 citations46
US7148324B1Dec 12, 2006
Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
DENDREON CORP1 citations46
US8354507B2Jan 15, 2013
HLA-DR specific antibodies, compositions and methods
DENDREON CORP0 citations42
BN IMMUNOTHERAPEUTICS INC
3 patentsUS7807146B2Oct 5, 2010
Methods for treating cancer with a recombinant MVA expressing HER-2
BN IMMUNOTHERAPEUTICS INC18 citations90
US8377688B2Feb 19, 2013
Use of MVA to treat prostate cancer
BN IMMUNOTHERAPEUTICS INC26 citations88
US7867483B2Jan 11, 2011
Use of MVA to treat prostate cancer
BN IMMUNOTHERAPEUTICS INC15 citations88